Thomas Jason Simon
Hospitalist · New Orleans, LANPI 1245807957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $619 and has fallen 90.8% since, to $57 in 2025.
Across 68 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$159
- Adamas Pharmaceuticals, Inc.$133
- Teva Pharmaceuticals USA, Inc.$109
- AbbVie$85
- Biogen$82
- Acadia Pharmaceuticals Inc$73
- plus $594 from 20 others
What the payments were for
- Food & beverage$1,234100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$109
How this compares
$1,234 in reported general payments places this provider in the 85th percentile of 301 hospitalist providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $21,628 |
| MounjaroTirzepatide | 11 | $11,810 |
| EliquisApixaban | 13 | $10,240 |
| TradjentaLinagliptin | 11 | $5,813 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,344 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $1,104 |
| Gabapentin | 55 | $944 |
| Ventolin HfaAlbuterol Sulfate | 12 | $718 |
| Omeprazole | 40 | $697 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 11 | $648 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $560 |
| Amlodipine Besylate | 95 | $509 |
| Duloxetine Hcl | 28 | $463 |
| Atorvastatin Calcium | 81 | $419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $5423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 301 hospitalist providers in Louisiana.
Other hospitalist in New Orleans
- Nikhil SharmaNew Orleans$5K
- Michael ConnerNew Orleans$3K
- Bipasha NathNew Orleans$2K
- Philip PutnamNew Orleans$2K
- Jacob DubucNew Orleans$2K
- Francisco Tirado-PoloNew Orleans$2K
- Kateryna PooleNew Orleans$2K
- Jason StencelNew Orleans$2K
- Morgan LinkNew Orleans$1K
- Robert AndresNew Orleans$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.